We're super excited to announce that Menten AI is now funded by Y Combinator! We're extremely grateful to everyone at Y Combinator for their guidance, especially in these unprecedented times.❤️🙏read more
Menten leverages synthetic biology, machine learning, and quantum computing to create new proteins not found in nature for diverse applications in the pharmaceutical and chemical industries.
Our hybrid quantum-classical computing approach allows us to create new biology and overcome the scalability challenges that limit classical approaches.
Reimagining next-generation peptide therapeutics with improved chemical and physical properties including extended plasma half-life and permeability.
We design de novo proteins that serve as delivery systems for specific intracellular biologics.
We employ a mixed approach of active site optimization, machine learning (sequence model prediction, reinforcement learning, quantum machine learning), and molecular dynamic approaches to pre-screen enzyme sequences and computationally optimize activity, specificity, and stability.